Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence | Zendy

Eugenia OviedoJoekes | Zendy; Daphne Guh | Zendy; Suzanne Brissette | Zendy; Kirsten Marchand | Zendy; Scott Macdonald | Zendy; Kurt Lock | Zendy; Scott Harrison | Zendy; Amin Janmohamed | Zendy; Aslam H. Anis | Zendy; Michael Krausz | Zendy; David C. Marsh | Zendy; Martin T. Schechter | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence

Author(s) -

Eugenia OviedoJoekes,

Daphne Guh,

Suzanne Brissette,

Kirsten Marchand,

Scott Macdonald,

Kurt Lock,

Scott Harrison,

Amin Janmohamed,

Aslam H. Anis,

Michael Krausz,

David C. Marsh,

Martin T. Schechter

Publication year - 2016

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2016.0109

Subject(s) - hydromorphone , medicine , heroin , opioid , randomized controlled trial , opioid use disorder , anesthesia , pharmacology , drug , receptor

Diacetylmorphine hydrochloride (the active ingredient in heroin), delivered under supervision, is effective for the treatment of severe opioid use disorder. However, owing to political and regulatory barriers, it is not available in many settings around the world, which limits the options for many long-term street opioid injectors not attracted into or retained in available treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research